Analysts predict that Horizon Pharma PLC (NASDAQ:HZNP) will post sales of $278.03 million for the current quarter, according to Zacks. Three analysts have issued estimates for Horizon Pharma’s earnings. The highest sales estimate is $283.79 million and the lowest is $274.10 million. Horizon Pharma posted sales of $289.51 million during the same quarter last year, which suggests a negative year-over-year growth rate of 4%. The firm is expected to report its next earnings report on Monday, August 6th.
On average, analysts expect that Horizon Pharma will report full-year sales of $1.17 billion for the current fiscal year, with estimates ranging from $1.17 billion to $1.18 billion. For the next year, analysts anticipate that the company will post sales of $1.28 billion per share, with estimates ranging from $1.23 billion to $1.33 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Horizon Pharma.
Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.08). Horizon Pharma had a negative net margin of 45.06% and a positive return on equity of 16.97%. The business had revenue of $223.88 million during the quarter, compared to analysts’ expectations of $232.05 million. During the same quarter last year, the company earned $0.21 EPS. The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year.
HZNP has been the subject of several research reports. BidaskClub upgraded shares of Horizon Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, March 3rd. ValuEngine downgraded shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, March 13th. Cantor Fitzgerald reiterated a “buy” rating and issued a $17.00 price target on shares of Horizon Pharma in a research report on Wednesday, March 14th. Zacks Investment Research downgraded shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Friday, May 4th. Finally, Mizuho restated a “buy” rating and set a $18.00 price objective on shares of Horizon Pharma in a research report on Monday, May 7th. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $19.40.
In other news, EVP Brian K. Beeler sold 15,433 shares of the company’s stock in a transaction on Friday, June 8th. The shares were sold at an average price of $17.58, for a total transaction of $271,312.14. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Chairman Timothy P. Walbert sold 83,353 shares of the stock in a transaction dated Friday, June 1st. The shares were sold at an average price of $16.17, for a total transaction of $1,347,818.01. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 116,717 shares of company stock worth $1,907,999. Corporate insiders own 3.90% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Trexquant Investment LP bought a new stake in shares of Horizon Pharma during the first quarter valued at about $2,008,000. American Century Companies Inc. raised its stake in shares of Horizon Pharma by 158.5% during the first quarter. American Century Companies Inc. now owns 706,775 shares of the biopharmaceutical company’s stock valued at $10,036,000 after purchasing an additional 433,359 shares in the last quarter. Systematic Financial Management LP bought a new stake in shares of Horizon Pharma during the first quarter valued at about $1,428,000. Federated Investors Inc. PA raised its stake in shares of Horizon Pharma by 140.8% during the first quarter. Federated Investors Inc. PA now owns 639,867 shares of the biopharmaceutical company’s stock valued at $9,086,000 after purchasing an additional 374,107 shares in the last quarter. Finally, Swiss National Bank raised its stake in shares of Horizon Pharma by 2.9% during the fourth quarter. Swiss National Bank now owns 278,156 shares of the biopharmaceutical company’s stock valued at $4,061,000 after purchasing an additional 7,800 shares in the last quarter. 84.99% of the stock is currently owned by hedge funds and other institutional investors.
HZNP stock traded up $0.16 on Tuesday, hitting $16.56. The company’s stock had a trading volume of 1,635,392 shares, compared to its average volume of 2,138,329. Horizon Pharma has a 1 year low of $11.17 and a 1 year high of $18.23. The company has a market cap of $2.73 billion, a price-to-earnings ratio of 14.03, a price-to-earnings-growth ratio of 1.00 and a beta of 1.36. The company has a debt-to-equity ratio of 2.17, a current ratio of 1.56 and a quick ratio of 1.50.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
Get a free copy of the Zacks research report on Horizon Pharma (HZNP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.